Beijing Succeeder Technology Inc (688338) Fair Value & Analysis
Healthcare · CN · Market cap 2.6B CNY
Fair value as of: Jun 24, 2026
Analysis
Beijing Succeeder Technology Inc (688338) currently trades at ¥26.90, while our model-based Fair Value estimate is ¥18.06 — implying the stock looks roughly 32.9% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
About the company
Beijing Succeeder Technology Inc. engages in the research and development, manufacture, and sale of in-vitro diagnostic products in China and internationally. The company offers coagulation testers, hemorheology testers, erythrocyte sedimentation testers, platelet aggregation testers, diagnostic reagents, quality control products. Its products are used in the prevention, screening, diagnosis, and monitoring of thrombophilia, coronary heart disease, venous thromboembolism, and other thrombotic and bleeding disorders. Beijing Succeeder Technology Inc. was founded in 2003 and is based in Beijing, China.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Beijing Succeeder Technology Inc (688338) undervalued?
What is the fair value of 688338?
What is the quality score of 688338?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.